75F40120C00150

FDABAA -20-00123 ROBUST IN VITRO/IN SILICO MODEL TO ACCELERATE GENERIC DRUG PRODUCT DEVELOPMENT FOR THE ORAL CAVITY ROUTE OF ADMINISTRATION

Award details

Obligations, current value and potential value describe different measures; they are never added together.

Field	Reported value
Agency	Department of Health and Human Services
Office	FDA OFFICE OF ACQ GRANT SVCS
NAICS	541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSC	B506 — Data Analysis (other than scientific)
Parent award / vehicle	Not reported
Set-aside	NO SET ASIDE USED.
Pricing type	COST NO FEE
Obligations	$1.2M
Current contract value	$1.2M
Potential contract value / ceiling	$1.2M
Start date	Sep 28, 2020
Current end date	Jun 29, 2025
Potential end date	Jun 29, 2025
Latest award activity	Jul 24, 2026
Source loaded	Sep 26, 2026

Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.

Date	Modification	Obligation change	Description
Jul 24, 2026	P00006	$-2	DEOBLIGATION/CLOSEOUT
Dec 13, 2023	P00005	$0	THE PURPOSE OF THIS MODIFICATION IS TO ALLOW FOR APPROVED / REQUESTED COST SHARE LEVEL: 1.2 PERSON MONTHS/YEAR FOR THE REMAINING 21 MONTHS OF THE CONTRACT.
Mar 8, 2023	P00004	$0	FDABAA -20-00123 ROBUST IN VITRO/IN SILICO MODEL TO ACCELERATE GENERIC DRUG PRODUCT DEVELOPMENT FOR THE ORAL CAVITY ROUTE OF ADMINISTRATION
Jul 20, 2022	P00003	$0	FDABAA -20-00123 ROBUST IN VITRO/IN SILICO MODEL TO ACCELERATE GENERIC DRUG PRODUCT DEVELOPMENT FOR THE ORAL CAVITY ROUTE OF ADMINISTRATION
Nov 5, 2021	P00002	$0	EO14042 INCORPORATING FAR 52.223-99, ENSURING ADEQUATE COVID-19 SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS (OCT 2021) (DEVIATION).
Mar 4, 2021	P00001	$0	FDABAA -20-00123 ROBUST IN VITRO/IN SILICO MODEL TO ACCELERATE GENERIC DRUG PRODUCT DEVELOPMENT FOR THE ORAL CAVITY ROUTE OF ADMINISTRATION
Sep 28, 2020	0	$1.2M	FDABAA -20-00123 ROBUST IN VITRO/IN SILICO MODEL TO ACCELERATE GENERIC DRUG PRODUCT DEVELOPMENT FOR THE ORAL CAVITY ROUTE OF ADMINISTRATION